Literature DB >> 29734296

Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses.

Ken Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29734296     DOI： 10.1038/nbt0518-378

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  IDO inhibitors move center stage in immuno-oncology.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2015-04       Impact factor: 54.908

2.  Industry pursues co-stimulatory receptor immunomodulators to treat cancer.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

3.  Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.

Authors:  Aron M Levin; Darren L Bates; Aaron M Ring; Carsten Krieg; Jack T Lin; Leon Su; Ignacio Moraga; Miro E Raeber; Gregory R Bowman; Paul Novick; Vijay S Pande; C Garrison Fathman; Onur Boyman; K Christopher Garcia
Journal:  Nature       Date:  2012-03-25       Impact factor: 49.962
  3 in total
  3 in total

1.  Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.

Authors:  Barbara Ziffels; Marco Stringhini; Philipp Probst; Tim Fugmann; Theo Sturm; Dario Neri
Journal:  Mol Cancer Ther       Date:  2019-06-18       Impact factor: 6.261

2.  Memory CD4 T cell-derived IL-2 synergizes with viral infection to exacerbate lung inflammation.

Authors:  K Kai McKinstry; Fahmida Alam; Valeria Flores-Malavet; Mate Z Nagy; Stewart Sell; Andrea M Cooper; Susan L Swain; Tara M Strutt
Journal:  PLoS Pathog       Date:  2019-08-14       Impact factor: 6.823

3.  TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity.

Authors:  Jun-Young Lee; Eunjin Lee; Sung-Wook Hong; Daeun Kim; O Eunju; Jonathan Sprent; Sin-Hyeog Im; You Jeong Lee; Charles D Surh
Journal:  Oncoimmunology       Date:  2019-11-04       Impact factor: 8.110
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.